Q3 Earnings Estimate for CorMedix Issued By Leerink Partnrs

CorMedix Inc (NASDAQ:CRMD) – Analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of CorMedix in a research note issued on Tuesday, September 23rd. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings of $0.57 per share for the quarter. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $1.91 EPS, FY2026 earnings at $2.91 EPS, FY2027 earnings at $3.06 EPS and FY2028 earnings at $3.50 EPS.

Several other research firms also recently weighed in on CRMD. D. Boral Capital downgraded CorMedix from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Needham & Company LLC boosted their target price on CorMedix from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 price objective on shares of CorMedix in a research report on Tuesday, September 9th. HC Wainwright decreased their price objective on CorMedix from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Finally, D Boral Capital cut CorMedix from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, CorMedix currently has an average rating of “Moderate Buy” and an average price target of $18.00.

CorMedix Stock Performance

CorMedix stock opened at $11.12 on Thursday. CorMedix has a fifty-two week low of $5.60 and a fifty-two week high of $17.43. The company has a market capitalization of $868.03 million, a P/E ratio of 14.83 and a beta of 1.76. The stock has a 50-day simple moving average of $12.34 and a 200-day simple moving average of $11.30.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.08. CorMedix had a return on equity of 42.73% and a net margin of 42.11%.The company had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. During the same period in the previous year, the business earned ($0.25) EPS. CorMedix’s revenue for the quarter was up 4830.1% on a year-over-year basis.

Insider Transactions at CorMedix

In related news, Director Alan W. Dunton sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $13.13, for a total value of $131,300.00. Following the completion of the transaction, the director directly owned 40,250 shares of the company’s stock, valued at $528,482.50. This trade represents a 19.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kaufman Beth Zelnick sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $13.41, for a total value of $670,500.00. Following the completion of the transaction, the insider directly owned 180,418 shares of the company’s stock, valued at $2,419,405.38. The trade was a 21.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 163,997 shares of company stock valued at $2,163,617. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On CorMedix

Hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas purchased a new position in CorMedix in the 1st quarter valued at approximately $98,000. Essex Financial Services Inc. purchased a new position in CorMedix during the first quarter worth $63,000. Swiss National Bank purchased a new position in CorMedix during the first quarter worth $724,000. Trexquant Investment LP increased its position in CorMedix by 588.9% during the first quarter. Trexquant Investment LP now owns 135,487 shares of the company’s stock worth $835,000 after buying an additional 115,819 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in CorMedix by 92.2% during the fourth quarter. ProShare Advisors LLC now owns 19,947 shares of the company’s stock worth $162,000 after buying an additional 9,568 shares in the last quarter. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.